Intervention thresholds for osteoporosis in the UK
- 15 December 2004
- Vol. 36 (1) , 22-32
- https://doi.org/10.1016/j.bone.2004.08.018
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Cost effectiveness of raloxifene in the treatment of osteoporosis in SwedenPharmacoEconomics, 2004
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003
- The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With OsteoporosisJournal of Bone and Mineral Research, 2003
- Cost Effectiveness of Alendronate (Fosamax??) for the Treatment of Osteoporosis and Prevention of FracturesPharmacoEconomics, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?Published by Oxford University Press (OUP) ,2001
- Statin therapy - what now?Drug and Therapeutics Bulletin, 2001
- Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical SynthesisJournal of Bone and Mineral Research, 2000
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- Cost-effectiveness of Fracture Prevention in Established OsteoporosisScandinavian Journal of Rheumatology, 1996